Eric Rochat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric Rochat has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Sarah Valencia
Duke University Medical Center, Duke Human Vaccine Institute, Durham, USA
2 shared publications Alaattin Erkanli
Department of Biostatistics and Bioinformatics, Duke University Hospital, Durham, NC (Mr Weber and Dr Erkanli)
1 shared publicationAmit Kumar
Duke University Medical Center, Duke Human Vaccine Institute, Durham, USA
1 shared publicationBhavna Hora
Duke University Medical Center, Duke Human Vaccine Institute, Durham, USA
1 shared publicationBrenna L. Hughes
Department of Obstetrics and Gynecology, Duke University Hospital, Durham, NC (Drs Gatta, Dotters-Katz, and Hughes); Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Hospital, Durham, NC (Drs Gatta, Dotters-Katz, and Hughes)
1 shared publication- Dai Wang
Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA
1 shared publication
Latest Publications
- Open Access
- 10 October 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-8
Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection
Human Cytomegalovirus (HCMV) is the leading infectious congenital infection globally and the most common viral infection in transplant recipients, therefore identifying a vaccine for HCMV is a top priority. Humoral immunity is a correlate of protection for HCMV infection. The most effective vaccine tested to date, which achieved 50% reduction in acquisition of HCMV, was comprised of the glycoprotein B protein given with an oil-in-water emulsion adjuvant MF59. We characterize gB-specific monoclonal antibodies isolated from individuals vaccinated with a disabled infectious single cycle (DISC) CMV vaccine, V160, and compare these to the gB-specific monoclonal antibody repertoire isolated from naturally-infected individuals. We find that vaccination with V160 resulted in gB-specific antibodies that bound homogenously to gB expressed on the surface of a cell in contrast to antibodies isolated from natural infection which variably bound to cell-associated gB. Vaccination resulted in a similar breadth of gB-specific antibodies, with binding profile to gB genotypes 1–5 comparable to that of natural infection. Few gB-specific neutralizing antibodies were isolated from V160 vaccinees and fewer antibodies had identifiable gB antigenic domain specificity compared to that of naturally-infected individuals. We also show that glycosylation of gB residue N73 may shield binding of gB-specific antibodies.
- 10 October 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-8
Open AccessVaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection
Human Cytomegalovirus (HCMV) is the leading infectious congenital infection globally and the most common viral infection in transplant recipients, therefore identifying a vaccine for HCMV is a top priority. Humoral immunity is a correlate of protection for HCMV infection. The most effective vaccine tested to date, which achieved 50% reduction in acquisition of HCMV, was comprised of the glycoprotein B protein given with an oil-in-water emulsion adjuvant MF59. We characterize gB-specific monoclonal antibodies isolated from individuals vaccinated with a disabled infectious single cycle (DISC) CMV vaccine, V160, and compare these to the gB-specific monoclonal antibody repertoire isolated from naturally-infected individuals. We find that vaccination with V160 resulted in gB-specific antibodies that bound homogenously to gB expressed on the surface of a cell in contrast to antibodies isolated from natural infection which variably bound to cell-associated gB. Vaccination resulted in a similar breadth of gB-specific antibodies, with binding profile to gB genotypes 1–5 comparable to that of natural infection. Few gB-specific neutralizing antibodies were isolated from V160 vaccinees and fewer antibodies had identifiable gB antigenic domain specificity compared to that of naturally-infected individuals. We also show that glycosylation of gB residue N73 may shield binding of gB-specific antibodies.
- 3 January 2022
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 4 (2) , 100560
Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women
- 3 January 2022
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 4 (2) , 100560
Clinical factors associated with cytomegalovirus shedding among seropositive pregnant women